RESEARCH TRIANGLE PARK, N.C., Feb. 2, 2016 /PRNewswire/ -- Cloud Pharmaceuticals, Inc., a cloud-based drug design and development company, today announced the completion of 17 new drug discovery projects. The company applied its Quantum Molecular Design process to design molecules targeting a wide range of indications. This effort has resulted in multiple development programs including those that target AMPK, eiF4E, Metnase, MTH1, PERK, and others. This volume of projects enabled Cloud Pharmaceuticals to pass the "millennium mark," an important milestone in its computational drug discovery program where it applied more than the equivalent of 1,000 years of high performance cloud computing time to conduct research in 2015.
"Over the past year, much of our work has focused on several areas of therapeutic focus including cancer, metabolic and cardiovascular disease, and central nervous system disorders," says Ed Addison, CEO, Cloud Pharmaceuticals. "We attribute this trend to the strength of our proprietary design process, but also because we have scientific advisors with specific expertise in those areas of research."
The company's scientific advisory board is comprised of leaders from industry and academia with expertise in neurological disorders, complex molecular and macromolecular systems, biophysics, translational research, and drug discovery and development. Members of the advisory board include Robert A. Hromas, MD, FACP, Martin Ogletree, PhD, and Jeff Vaught, PhD. The advisors collaborate with Cloud Pharmaceuticals' board of directors and company leadership to provide insight on needs and opportunities within the pharmaceutical industry.
"Our strategy is to work with organizations to jointly design new drugs and then partner with later-stage developers. The results we've achieved demonstrate that our process is working and resulting in low-cost, high-value molecules," Addison says.
Cloud Pharmaceuticals is working with partners to develop a pipeline of fractionally-owned drugs and a focused pipeline of wholly-owned drugs. Its partnerships include a relationship with THERAMetrics to design and develop therapeutics for orphan CNS diseases and other indications. It is also collaborating with the University of Florida Department of Medicine to share intellectual property and jointly fund 12 research projects. The collaboration has resulted in the design of multiple novel inhibitors of the MTH1 protein, an enzyme required for cancer cell proliferation.
Cloud Pharmaceuticals has the capacity to design molecules to drug many more targets and is actively seeking partnerships to collaborate on this effort. To learn more about the company's partnering relationships and resulting drug discovery projects, please visit http://www.cloudpharmaceuticals.com/partnering.html.
About Cloud Pharmaceuticals, Inc.
Cloud Pharmaceuticals is committed to improving health and well-being through the computational design and rapid development of new medicines. The company's Quantum Molecular Design process designs drug candidates that are qualified for development from the outset, enabling faster progress at lower cost and a higher success rate. The company partners at all stages of drug development – from discovery through the clinic – and is building an extensive product pipeline that spans a wide range of indications. For information visit www.cloudpharmaceuticals.com.
SOURCE Cloud Pharmaceuticals, Inc.